Scotia Capital’s AnaptysBio ANAB Stock Holding History

Scotia Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,082	Closed	-$187K	–	866
2025 Q1	$187K	Buy	+10,082	New	+$168K	﹤0.01%	788

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Scotia Capital's ANAB Position: Q2 2025 in Review

Scotia Capital sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 10,082 shares — an estimated $187K sold.

Scotia Capital first reported a position in ANAB in Q1 2025 and held it in 1 quarter. The position peaked at $187K in Q1 2025. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

Scotia Capital reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
Scotia Capital sold 10,082 AnaptysBio shares in Q2 2025, an estimated $187K.
Scotia Capital first reported a position in AnaptysBio in Q1 2025 and held it in 1 quarter.
Scotia Capital's AnaptysBio position peaked at $187K in Q1 2025.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on Scotia Capital's 13F filing for Q2 2025, filed 13 Aug 2025.